Who are ActiveMatrix's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Doxycycline (Oracea), Amzeeq 4% Topical Foam, Interferon beta 1a, oral doxycycline, MMP with Saline infusion, local tetracycline, Doxycycline and tauroursodeoxycholic acid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/activematrix.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ActiveMatrix — Competitive Intelligence Brief

ActiveMatrix (ActiveMatrix) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: matrix metalloproteinase inhibitor. Area: Oncology.

marketed matrix metalloproteinase inhibitor matrix metalloproteinases Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ActiveMatrix (ActiveMatrix) — Baylor College of Medicine. ActiveMatrix is a matrix metalloproteinase inhibitor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ActiveMatrix TARGET	ActiveMatrix	Baylor College of Medicine	marketed	matrix metalloproteinase inhibitor	matrix metalloproteinases
Doxycycline (Oracea)	Doxycycline (Oracea)	LEO Pharma	marketed	Tetracycline antibiotic (anti-inflammatory formulation)	Matrix metalloproteinases (MMPs); 30S ribosomal subunit
Amzeeq 4% Topical Foam	Amzeeq 4% Topical Foam	Edward Lain, MD	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit; matrix metalloproteinases
Interferon beta 1a, oral doxycycline	Interferon beta 1a, oral doxycycline	Louisiana State University Health Sciences Center Shreveport	marketed	Cytokine + tetracycline antibiotic combination	Interferon-beta receptor (IFNBR); doxycycline targets bacterial ribosomes and matrix metalloproteinases
MMP with Saline infusion	MMP with Saline infusion	Clinica Dermatologica Arbache ltda	marketed	Enzymatic dermatological agent	Matrix metalloproteinases (MMPs)
local tetracycline	local tetracycline	The Forsyth Institute	phase 3	Matrix metalloproteinase inhibitor	Matrix metalloproteinases (MMPs)
Doxycycline and tauroursodeoxycholic acid	Doxycycline and tauroursodeoxycholic acid	Fondazione IRCCS Policlinico San Matteo di Pavia	phase 3	Combination therapy (antibiotic + bile acid derivative)	Matrix metalloproteinases, FXR (farnesoid X receptor), TGR5 (G-protein coupled bile acid receptor 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (matrix metalloproteinase inhibitor class)

Baylor College of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ActiveMatrix — Competitive Intelligence Brief. https://druglandscape.com/ci/activematrix. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab